Mergers and acquisitions – Page 12
-
BusinessMerger creates biggest supplier of unlicensed drugs
Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
Business
BMS invests in gene therapy
Bristol-Myers Squibb makes $100 million deal with biotech uniQure
-
Business
Horizon to acquire orphan drugs in $1.1bn Hyperion takeover
Horizon will buy Hyperion and add new drugs to its rare disease portfolio
-
Business
Dow sells off chlorine assets in $5bn deal
US chemical giant disposes of unwanted operations in tax-free deal
-
Business
Sun Pharma snares Ranbaxy in $4bn deal
Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world
-
Business
Teva buys Auspex Pharmaceuticals for $3.2bn
Generics giant will add late stage Huntingdon’s drug to CNS portfolio
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
Business
Mallinckrodt to buy Ikaria to expand in US hospitals
$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
Business
Asahi Kasei to buy Polypore for battery materials
$2.2bn deal adds to Japanese consolidation in energy storage
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
WR Grace to split in half
Two daughter companies will focus on catalysts and speciality construction chemicals
-
Business
Tronox to buy FMC’s alkali chemicals
$1.6bn deal helps Tronox strengthen its inorganics portfolio as FMC shifts towards agrochemicals
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments